Discharge Standards for Pretreatment Effluent from GSK-Hamilton Pharmaceuticals in Montana (NPDES Regulations)
The GSK-Hamilton campus hosts buildings dedicated to manufacturing MPL and QS-21 adjuvants for pharmaceutical purposes. These products are sent to other GSK locations for vaccine formulation before they're shipped out. Owned by Corixa Corporation dba GlaxoSmithKline Vaccines, this facility has authorization under the Pretreatment Notice of Discharge Requirements, MT-PF00103, to discharge wastewaters generated from these processes. However, the specific discharge requirements for this facility remain unclear from public records.
Commonly, permits for pharmaceutical manufacturing wastewater pretreatment in Montana and similar jurisdictions would set limits for factors such as chemical oxygen demand (COD), biochemical oxygen demand (BOD), total suspended solids (TSS), pH, toxic metals (e.g., mercury, lead, cadmium), and specific pharmaceuticals or active ingredients. Facilities typically need to monitor these parameters regularly to maintain compliance.
Additionally, such permits would require the implementation of pretreatment technologies or processes to reduce pollutant loads before discharge. Facilities must also submit periodic discharge monitoring reports (DMRs) to demonstrate compliance and are usually prohibited from discharging substances that interfere with wastewater treatment plants or pose risks to human health or the environment.
For the precise limits, conditions, and parameters specific to the GSK-Hamilton facility's discharge, you should consult the official Pretreatment Notice of Discharge Requirements MT-PF00103 document issued by the Montana Department of Environmental Quality (DEQ) or an equivalent regulatory body. Accessing this permit document directly from the Montana DEQ website or contacting GSK-Hamilton's environmental compliance office would be necessary for detailed information.
){kind=link}